baber/WOPTO huggingface dataset:
Patent NZ-512082-A (NZ)
Title: A method and means for producing a feed product containing a mixture of krill hydrolysate or fresh krill and a dry carrier (plant protein, dry krill, fish or byproduct meal)
Inventor: SAXBY DAVID J
IPC: A23J1/04
Filed: 1998-02-09
Abstract: A method and apparatus used in producing a feed product or premix and the products made by the method is described.  A predetermined quantity of krill hydrolsyate is added to a predetermined quantity of dry carrier with or without a predetermined quantity of liquid marine protein.  The mixture is subject to evaporation and drying steps in which heavier particles are separated from relatively lighter particles.  The mixture may be blended, ground and subject to chemical reaction in a balance tank prior to entering a dryer.  The dryer utilizes a warm air source, a tower and cyclone to dry the mixture following its entry into the dryer.  Temperature sensitive enzymes or other bioactive products may be added to the product produced from the dryer.  A method for obtaining enzymes from a fresh krill extract or an autolysed krill preparation and the product are also disclosed.  A method for separating the bound protein and pigments from crustacean waste using krill enzymes and a product produced by the method are also described.
Patent NZ-512507-A (NZ)
Title: Separating components from vegetable material that has leaf and/or stem parts separated into fibre fraction and juice stream having soft tissues such as parenchyma and cytosol
Inventor: HULST ANNE COENRAAD
IPC: A23L19/00
Filed: 1999-12-24
Abstract: The invention relates to the separation and recovery of components from vegetable raw materials. The invention provides a method for separating components from vegetable material which comprises at least leaf and/or stem parts, characterized in that the material is at the least partly fiberized and subsequently is separated into a fiber fraction and a juice stream, such that the fiber fraction principally comprises relatively firm tissues such as epidermis, sclerenchyma and vascular bundles, and the juice stream principally contains soft tissues such as parenchyma and cytosol. In a preferred embodiment, the invention provides a method for separating a juice stream which comprises in particular chloroplasts.
Patent NZ-512684-A (NZ)
Title: Salts of (R)- or (S)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide useful in treating central nervous system disorders
Inventor: BERG STEFAN
IPC: A61P35/00
Filed: 2000-01-14
Abstract: A pharmaceutically acceptable salt of a compound of formula (I) or a solvate of the salt is described wherein the compound is the (R)-enantiomer, (S) enantiomer or the racemate limited by the proviso listed in the specification is useful for 5-hydroxytryptamine mediated disorders.
Patent NZ-513902-A (NZ)
Title: 1-deoxy-D-xylulose-5-phosphate reductoisomerases, and methods of use
Inventor: CROTEAU RODNEY R
IPC: C12N15/53
Filed: 2000-01-27
Abstract: An isolated nucleic acid molecule that hybridizes under stringent conditions to the nucleic acid of SEQ ID NO:1, provided that the nucleic acid does not consist of a nucleic acid sequence selected from SEQ ID NO: 10 and SEQ ID NO:11, is described. The nucleic acid encodes for a 1- deoxy-D-xylulose-5-phosphate reductoisomerase protein, preferably from an essential oil plant i.e. Mentha. Also described are vectors comprising the nucleic acid, cell transformed with vectors and methods for enhancing or reducing the level of expression of the protein in a cell.
Patent NZ-517144-A (NZ)
Title: Point of sale payment terminal
Inventor: TEMPLETON RANDY
IPC: G06Q20/00
Filed: 2000-08-09
Abstract: An integrated point of sale terminal for processing multiple payment memory is disclosed. The housing (12) has a base shaped to sit on a merchant counter and has a document slot for receiving a check. The processor is disposed in the housing (12), and the memory is in communication with the processor. The payment terminal (10) is located at the point of sale during use to allow a store merchant to accept multiple payment types. The payment terminal (10) further includes a magnetic ink character recognition device for reading a string of magnetic ink characters on the check which is affixed to the housing (12) at the document slot and is in communication with the processor. Further, the payment terminal (10) includes an imaging device for capturing an image of the check. The imaging device is affixed to the housing (12) at the document slot and is in communication with the processor.
Patent NZ-517622-A (NZ)
Title: Combined vaccine composition comprising HBV and HPV antigens with a TH1 adjuvant
Inventor: WETTENDORFF MARTINE ANNE CECIL
IPC: A61K39/29
Filed: 2000-09-06
Abstract: A  vaccine composition comprising a hepatitis B  viral antigen  (HVB) and a human papillomavirus (HPV)  antigen  in conjunction   with  an  adjuvant  which  is  a  preferential stimulator  of  TH1 cell response such as 3D-MPL  and  QS21, wherein  the vaccine composition does not comprise a  herpes simplex  viral  antigen, and optionally in addition  one  or more  of  the  following:  an EBV  antigen,  a  hepatitis  A antigen  or  inactivated attenuated virus, a herpes  simplex viral  antigen, a VZV antigen, a HCMV antigen, a  Toxoplasma gondii antigen is disclosed.
Patent NZ-518584-A (NZ)
Title: Apparatus for packaging insulation material
Inventor: COPELAND THOMAS P
IPC: B65H18/22
Filed: 2000-10-27
Abstract: A belt roll-up machine for in-line packaging of insulation material has a pair of endless belts 26,27 carried by the main frame that have portions that overlap each other to form a loop. A compressible strip of insulation material may be rolled in the loop.
Patent NZ-519546-A (NZ)
Title: Betaglycan as an inhibin receptor and uses thereof
Inventor: VALE WYLIE
IPC: A61K48/00
Filed: 2000-12-14
Abstract: Describes the use of an anti-betaglycan antiserum directed against an extracellular epitope of betaglycan in the manufacture of a medicament for the augmentation of activin-induced signalling in a cell, wherein said antiserum inhibits the formation of inhibin/betaglycan complexes on the surface of said cell. Further described is the use of an antisense transcript of betaglycan in the manufacture of a medicament for the augmentation of activin-induced signalling in a cell, wherein said transcript inhibits the expression of betaglycan and the formation of inhibin/betaglycan complexes on the surface of said cell.
Patent NZ-520971-A (NZ)
Title: Mouthpiece for a particulate inhaler
Inventor: STANIFORTH JOHN NICHOLAS
IPC: A61M11/00
Filed: 2001-03-20
Abstract: A mouthpiece (11) for use in an inhaler (10) for a particulate medicament, the mouthpiece having: an inlet (13) and an outlet (14) for the particulate medicament; a number of abutments (16) which extend across the mouthpiece and which are arranged in a staggered configuration such that, in use, medicament is caused to break up as the medicament passes through the mouthpiece; wherein the abutments are blades having an elongate cross section in the direction of travel of the medicament.
Patent NZ-524657-A (NZ)
Title: 1 alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications
Inventor: DELUCA HECTOR F
IPC: A61P35/02
Filed: 2001-06-11
Abstract: The use of 1á-hydroxy-2-methylene-19-nor-homopregnacalciferol compound having the formula (I) in the manufacture of a medicament for the treatment of psoriasis, leukaemia, colon cancer, breast cancer, prostate cancer, multiple sclerosis, lupis, diabetes mellitus, host versus graft reaction, rejection of organ transplants, renal osteodystrophy, rheumatoid arthritis, asthma, inflammatory bowel disease or a skin condition selected from the group consisting of wrinkles, lack of adequate skin firmness, lack of adequate dermal hydration and insufficient sebum secretion; a method of treating a disease or skin condition with the compound provided that the subject is not human; and a cosmetic method of treating a skin condition selected from the group consisting of wrinkles, lack of adequate skin firmness, lack of adequate dermal hydration and insufficient sebum section comprising administering the compound to a patient.
Patent NZ-532286-A (NZ)
Title: Power generator and turbine unit
Inventor: SUSMAN HECTOR FILLIPUS ALEXAND
IPC: F03B11/02
Filed: 2002-10-04
Abstract: The present invention provides a power generator (8) comprising: at least one underwater turbine unit (10) including a housing (12) having a liquid flow channel (14) therethrough and at least one turbine means (16) mounted in the flow channel (14) for rotation in response to liquid flow through the flow channel (14). The turbine means (16) drives a pump means (18) that pumps fluid to the generator assembly (20). The power generator (8) generates electrical power. Channel (14) comprises a venturi comprising a symmetrical divergent-convergent-divergent venturi.
Patent NZ-532806-A (NZ)
Title: Preparation of trans-fused 3,3a,8,12b-tetrahydro-2H-dibenzo[3,4:6,7]cyclohepta[1,2-b]furan derivatives
Inventor: LANG YOLANDE LYDIA
IPC: A61P25/24
Filed: 2002-12-02
Abstract: A process for preparing each individual diastereoisomer of formula (I) wherein the substituents on carbon atoms 3a and 12b have the trans configuration, the substituent on carbon atom 2 may have the R or the S configuration, comprising the step of cyclizing a compound of formula (II) wherein R represents C1-3 alkylcarbonyl; OR1 represents a leaving group and the substituents -OR and -CH2-CHOH-CH2OR1 have the cis configuration, in a reaction inert solvent in the presence of an acid.
Patent NZ-535957-A (NZ)
Title: Condom that has a vasodilator active compound and a lubricant, which are immiscible, applied to its external surface
Inventor: BARDER JAMES HENRY
IPC: A61K9/00
Filed: 2003-04-14
Abstract: A condom has a vasodilator active compound applied to its external surface is described. The vasodilator is preferably disposed towards the open end of the condom whereby, in use during intercourse, the compound makes contact with the vaginal meatus or proximal region of the vagina, such that the vasodilator is absorbed through the lining of the vagina to stimulate and increase the flow of blood in the labia and through the clitoris to promote engorgement thereof to alleviate symptoms associated with female inorgasmia.
Patent NZ-536676-A (NZ)
Title: Combination neisserial compositions comprising amino acid sequences
Inventor: GIULIANI MARZIA MONICA
IPC: A61K38/16
Filed: 2000-05-19
Abstract: A composition is disclosed which comprises an isolated first protein and an isolated second protein. The first protein is depicted to comprise an amino acid sequence which has 70% or more sequence identity to SEQ ID NO:3516, 3518 and/or 3520 and/or is an antigenic fragment of 8 or more amino acids of SEQ ID NO:3516, 3518 and/or 3520. The second protein is described to comprise an amino acid sequence selected from SEQ ID NO:4004, 4006, 4007, 4009, 4011, 4013, 4015-4033, 4035, 4037, 4039, 4041, 4043, 6217-8347, 8349-8376 and even-numbered SEQ ID NOs:2-4002, and/or is an antigenic fragment of 8 or more amino acids SEQ ID NO:4004, 4006, 4007, 4009, 4011, 4013, 4015-4033, 4035, 4037, 4039, 4041, 4043, 6217-8347, 8349-8376 and even-numbered SEQ ID NOs:2-4002. There is a proviso that SEQ ID NOs:894, 896, 898, 2182, 2184 and/or 2186 are not selectable sequences nor compose a fragment of the second protein. The use of the first and second proteins is disclosed to be in the manufacture of a medicament for treating or preventing infection due to the Neisserial bacteria.
Patent NZ-537331-A (NZ)
Title: Diagnostics methods by determining T cell response to a protein and its epitope
Inventor: LALVANI AJIT
IPC: G01N33/50
Filed: 2003-07-07
Abstract: A method of diagnosing in an individual recent exposure to an agent which is a pathogen, vaccine or any other moiety which induces a cellular response, comprises determining in vitro whether the T cells of the individual recognise a protein from that agent having a length of at least 30 amino acids, to a greater extent than one or more peptide epitopes from the agent, a greater extent of recognition of the protein indicating that the individual has recently been exposed to the agent.
Patent NZ-537811-A (NZ)
Title: Crystal form II of 2-[2-(1-chlorocyclopropyl)-3-(2-chlorophenyl)-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazole-3-thione
Inventor: SEIDEL ERIKA
Filed: 2003-07-10
Abstract: Disclosed is crystal form II or 2-[2-(chlorocyclopropyl)-3-(2-chlorophenyl)-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazole-3-thione of the formula (A) as described in the specification. The disclosed crystal form is useful as an antimicrobial agent.
Patent NZ-537974-A (NZ)
Title: Macrocyclic pyrimidines, the production thereof and the use of the same as medicaments
Inventor: LUCKING ULRICH
Filed: 2003-08-05
Abstract: Disclosed is a compound of general formula (I) wherein the substituents are as defined in the specification. Compounds of the invention inhibit VEGF-receptor tyrosine kinases and cyclin-dependent kinases. They are useful for the treatment of cancer and other diseases related to cellular proliferation.
Patent NZ-542260-A (NZ)
Title: Treatment of intestinal conditions with mecamylamine
Inventor: DEVANE JOHN
IPC: A61K9/50
Filed: 2004-03-12
Abstract: Disclosed is the use of racemic, (R)-enriched or (S)-enriched N-2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the reduction of gastrointestinal motility in a subject suffering from an abnormal increase in gastrointestinal motility, wherein said abnormal increase in gastrointestinal motility is caused by at least one condition chosen from inflammatory bowel disease, ulcerative colitis, granulomatous enteritis, infectious diseases of the small or large intestine, pyloric spasm, abdominal cramps, a functional bowel disorder, mild dysenteries, diverticulitis, acute enterocolitis, neurogenic bowel disorders, splenic flexure syndrome, neurogenic colon, spastic colitis, or is a symptom of any of the foregoing conditions.
Patent NZ-543324-A (NZ)
Title: Toggle type telecommunications terminal blocks
Inventor: THOMPSON ROY KELLER
IPC: H01R4/24
Filed: 2004-04-06
Abstract: Telecommunications terminal blocks for making and breaking connections with a telecommunications conductor include a unitary base that defines a body cavity and having a hinge member at an end thereof. In other embodiments, the base includes a hinge member on an external surface thereof. First and second connectors are mounted in the base and extend into the body cavity. A toggle member is rotatably connected to the base at the hinge member. The toggle member has first and second conductor receiving openings therein and first and second conductor passages extending from the respective openings past the respective connectors. An environmental sealant material is positioned in the body cavity and may surround the connectors. A latching member allows rotation of the toggle member to a conductor receiving position or locks the toggle member in a conductor terminating position so that the conductor is electrically connected to the respective connector. A release member is configured to allow movement of the latching member and is positioned so that conductors extending from the openings do not pass adjacent to the release member.
Patent NZ-544295-A (NZ)
Title: Methods and compositions for controlling ectoparasites using bipyridine derivatives and analogs
Inventor: BOWLES VERNON MORRISON
IPC: A01N47/34
Filed: 2004-07-16
Abstract: Disclosed is the use of at least one metal chelating agent for treating ectoparasites, to inhibit hatching of the ectoparasite eggs, wherein the metal chelating agent is a compound of formula (1) or a pharmaceutically, veterinary or agriculturally acceptable salt thereof, wherein, X is a bond, -C(R5)2-, -Z-, or ûC(R5)2-Z-C(R5)2-, Z is a bond, -NH-, -O-, -S-, -C(O)-, or -C(S)-, and wherein the other substituents are as disclosed in the specification.
Patent NZ-564900-A (NZ)
Title: Cable grommet with integrated electrical port components
Inventor: CHONG JOSEPH
Filed: 2008-01-07
Abstract: An electrical grommet device is disclosed. In one exemplary embodiment, an electrical device (100) comprises a casing (105) having a grommet (110), one or more first apertures (111) and an insertion portion (117). A connection mechanism (150) is provided that is capable of being coupled to the grommet (110). The electrical device (100) further comprises one or more electrical components (130) located at least partially within the casing, and one or more electrical connectors (131) located at least partially within the casing (105) and coupled to the one or more electrical components (130). The electrical connectors (131) are accessible through one or more first apertures (111). The insertion portion (117) of the grommet (l10) can be removably placed in a grommet hole from a first side of the grommet hole, and the grommet (110) can be removably coupled to the connection mechanism (150) from a second side of the grommet hole, opposite the first side.
Patent NZ-569483-A (NZ)
Title: Use of alpha-hydroxy carbonyl compounds as reducing agents
Inventor: KNOX RICHARD JOHN
IPC: A61K31/045
Filed: 2006-12-29
Abstract: Disclosed herein is the use of a compound of formula I (an alpha-hydroxy carbonyl compound) as an activating agent for the conversion of a reduction-activated prodrug, such as metronidazole, Chloramphenicol, nitrofurazone, mitomycin C, mitosene, cyclopropamitosene, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide; to a corresponding active substance, wherein the substituents are as defined within the specification, and wherein the reduction i) is effected at a pH of between 7 and 11; or ii) is conducted in the presence of a base that is an amine, a nitrogen-based heterocycle or a carbonate or bicarbonate salt; furthermore the compound of formula I is capable of forming a cyclic dimer of formula Ia.
Patent NZ-570865-A (NZ)
Title: Alanine and valine prodrugs of nadifloxacin, S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid
Inventor: PATEL MAHESH VITHALBHAI
IPC: A61K31/4745
Filed: 2007-03-01
Abstract: Disclosed are sulfonic acid salts of alanine and valine prodrugs of nadifloxacin, S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, having the formula I, and processes for their preparation. The compounds can be used to treat bacterial Gram-positive, Gram-negative and anaerobic infections, especially infections caused by resistant Gram-positive organism and Gram-negative organism, mycobacterial infections and emerging nosocomial pathogen infections.
Patent NZ-571143-A (NZ)
Title: 1,2,4,5-Tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them
Inventor: PEGLION JEAN-LOUIS
IPC: A61K31/55
Filed: 2008-09-10
Abstract: Disclosed is a compound of formula (I) wherein X represents O, NH or CH2; wherein the rest of the substituents are disclosed within the specification, its optical isomers when they exist, and also addition salts thereof with a pharmaceutically acceptable acid. Also disclosed is a process of making the compounds of formula (I) and the use of the compounds of formula (I) in the manufacture of a medicament for treating pathologies in which the activity or expression of HCN channels is degraded and abnormal such as pathologies in which accelerated heart rate acts as a trigger or has an aggravating role.
Patent NZ-571562-A (NZ)
Title: A shopping method and system
Inventor: MEBRUER ROBERT-BRUCE
IPC: G06Q30/00
Filed: 2006-03-31
Abstract: A shopping system and method of for providing inducements to shoppers are disclosed. The system comprises an input device adapted to collect data relating to products purchased by individual shoppers automatically at a point of sale terminal and transmit the collected data via a communication link; a processor in data communication with the input device via the communication link; database in data communication with processor and adapted to store collected data for a plurality of shoppers; and an output in data communication with the processor. The processor is adapted to analyse the collected data relating to products purchased by individual shoppers to automatically identify core product categories by: grouping individual products into product categories based on purchase characteristics determined by analysing the collected data, and determining core product categories by identifying product categories having purchase characteristics meeting desired purchase criteria for a pre-defined market intention. The processor is further adapted to automatically establish related product categories which relate to the core product categories by, for each core product category: a) selecting a product from the core product category as a core product; b) determining a correlation between the core product and each other product purchased in a purchase transaction by a consumer which includes a purchase of the core product; c) determining a correlation score for each other product and ranking correlation scores for each other product from a strongest correlation score to a weakest correlation score, d) determining a correlation point between a strongest correlation score and a weakest correlation score to determine a cut-off of strong correlations from weak correlations; e) assigning each other product which has a correlation score of the correlation point or stronger as a related product to the core product category; f) grouping the related products into product categories based on product characteristics of the related product; and g) assigning these product categories as related product categories to the core product category. In part c) the correlation score is a value indicative of the correlation between a purchase of the core product and a purchase of the other product. The processor also is adapted to create a promotional offer list listing one or more promotional offers relating to core products and related products, and control the output to offer inducements, in the form of one or more promotional offers selected from the promotional offer list, to shoppers to purchase products.
Patent NZ-579899-A (NZ)
Title: Acetohydroxyacid synthase mutants
Inventor: MCELVER JOHN A
IPC: A01H5/00
Filed: 2008-04-03
Abstract: A mutant of the acetohydroxyacid synthase large subunit (AHASL) that has increased tolerance to a herbicide selected from imidazoliones, sulfonylureas, triazolopyrimidines and pyrimidinyloxybenzoates. The mutant is provided by three substitutions that can either be present in a single AHASL or split between two or three AHASLs. The substitutions are: a valine, threonine, glutamine, cysteine or methionine at position 122 of SEQ ID NO: 1 or position 90 of SEQ ID NO: 2; and alanine , glutamic acid, serine, phenylalanine, threonine, aspartic acid, cysteine or asparagine substitution at position 199 of SEQ ID NO: 1 or position 167 of SEQ ID NO:2; and a phenylalanine, asparagine, threonine, glycine, valine, isoleucine or tryptophan at position 653 of SEQ ID NO: 1 or position 621 of SEQ ID NO: 2.
Patent NZ-581932-A (NZ)
Title: High solids glyoxalated polyacrylamide
Inventor: WARD JAMES DREW
IPC: C08F8/28
Filed: 2008-06-13
Abstract: Disclosed is a glyoxalated polyacrylamide polymer composition comprising a glyoxalated polyacrylamide polymer in an amount of from about 10% to about 30% by weight of said composition, and comprising an aqueous medium, wherein said glyoxalated polyacrylamide polymer is obtained from the reaction between glyoxal and a cationic polyacrylamide base polymer comprising at least about 30% by weight cationic monomer, wherein the cationic polyacrylamide base polymer has a molecular weight ranging from about 3,000 Daltons to about 13,000 Daltons, and wherein the cationic polyacrylamide base polymer comprises from about 70% to about 50% by weight, acrylamide monomer and from about 30% to about 50%, by weight, cationic monomer copolymerizable with said acrylamide monomer. The polymer is used in paper making.